Donepezil Hydrochloride (E2020) in Dementia Associated With Cerebrovascular Disease

NCT00165737 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 974

Last updated 2011-04-01

No results posted yet for this study

Summary

Twenty-four week, prospective, randomized, double-blind, placebo-controlled, parallel-group study.

Conditions

  • Dementia, Vascular

Interventions

DRUG

Donepezil Hydrochloride

Sponsors & Collaborators

  • Eisai Inc.

    lead INDUSTRY

Principal Investigators

  • Holly Posner · Eisai Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
41 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-03-31
Primary Completion
2005-08-31
Completion
2006-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00165737 on ClinicalTrials.gov